Library Vision Mission And Objectives

When this observation is taken together with endostatins lack of toxicity, endostatin may someday be used chronically in a preventive mode for patients with a high cancer risk for breast cancer or other tumors.They received a daily intravenous bolus dose of endostatin over a period of minutes.Endostatin was safe and had a linear pharmacokinetic prof ile up to mgmday.Tumors regressed in two patients, although not suff iciently to satisfy the criteria for the terms partial or complete response used for chemotherapy.In one patient with metastatic melanoma there was prolonged stabilization for days with a much improved quality of life and he returned to work.The limited antitumor effect of bolus dosing in these patients is similar to the weak antitumor effect observed in mice that received bolus dosing.In these patients endostatin is showing more anticancer activity and more prolonged stable disease up to year or more.A biochemical approach was designed to extract vascular basement membranes and perform degradation with tumor microenvironment associated enzymes.The isolated vascular basement membrane per se, did not reveal any antiangiogenic activity in its solid state.But, degradation by various basement membranedegrading enzymes liberated cryptic domains of collagen molecules from the vascular basement membrane with novel antiangiogenic activity.Interestingly, while these fragments are present in the intact molecules, in this form they do not exhibit antiangiogenic activity.The initial screen of fragments from vascular basement membrane identif ied three antiangiogenic fragments from type IV collagen, known as arresten, canstatin and tumstatin.Endostatin was also identif ied in this collection of basement membrane fragments.Ar restin exhibits antiangiogenic activity in various in vitro and in vivo assays and is found circulating in normal individuals.Recombinant arresten inhibited the growth of small and large renal cell carcinoma xenografts and prostate carcinomaxenografts in nude mice at doses as low as mgkgday intraperitoneally.Two independent studies supportthe contention that arresten may function via integrin.Senger and colleagues demonstrate that integrinneutralizing antibodies can inhibit VEGF driven angiogenesis without detectable effect on preexisting vasculature, and VEGF can induce expression of and integrins.Canstatin exhibits antiangiogenic activity in several in vitro and in vivo assays.Established human prostate carcinoma mice exhibited fractional tumor volumes of about threefold less than placebotreated mice when treated with mgkg canstatin.This decrease in tumor size was consistent with a decrease in CD positive vasculature.Petitclerc and colleagues demonstrate that recombinant canstatin, tumstatin, and the NC domain can inhibit angiogenesis in a CAM assay.Petitclerc and colleagues also show that canstatin can bind to D-Cycloserine vinteg rin on endothelial cells.Kamphaus and colleagues investigated the effect of canstatin on ERK activation induced by fetal bovine serum and endothelial mitogens.Canstatin does not act primarily by inhibiting VEGF or bFGF activation of ERK.Instead, canstatin specif ically induces apoptosis of endothelial cells with insignif icant effect on nonendothelial cells.Apoptosis of endothelial cells by canstatin is mediated by induction of a steady decrease in FLIP protein levels in the presence of fetal calf serum, bFGF and VEGF.Interestingly, canstatin did not Heptaminol hydrochloride affect FLIP levels in the absence ofgrowth factors.Canstatins lack of effect on endothelial cells in the absence of growth factors may indicate that only proliferative endothelium is targeted.

Leave a Reply

Your email address will not be published. Required fields are marked *